Heartflow CEO John Farquhar sells $1.36m in common stock

John C.M. Farquhar, the Chief Executive Officer of Heartflow Inc., divested 27,230 shares of the company's common stock on August 21, 2026. The sale, amounting to $1,361,500, was executed at a rate of $50.0 per share and adhered to a Rule 10b5-1 trading plan Farquhar established on September 12, 2025. This move occurred as Heartflow's stock approached its 52-week peak of $51.19, following an impressive 117% increase over the past six months.

Post this transaction, Farquhar personally holds 360,814 shares of Heartflow's common stock. According to InvestingPro analysis, the stock is presently considered overvalued compared to its intrinsic value, positioning it among companies on the most overvalued list. Investors can explore further insights with 14 ProTips and detailed financial metrics for Heartflow Inc. via InvestingPro.

Concurrently, HeartFlow Inc. disclosed a modestly narrower-than-anticipated loss for the second quarter of 2026. Adjusted earnings per share stood at negative $0.07, surpassing Wall Street's forecast of negative $0.19 per share. The quarter's revenue amounted to $64.1 million, representing a 48% rise from the prior year and exceeding both Stifel's forecast of $56.7 million and the consensus estimate of $56.6 million.

This robust performance was credited to heightened demand for Heartflow's diagnostic tools for coronary artery disease and progress in its plaque and FFRCT divisions. Subsequently, Stifel upgraded its price target for HeartFlow shares to $45 from $40, maintaining a Buy rating. These developments underscore HeartFlow's capability to surpass market forecasts and spur growth in its principal business segments.

This account was AI-generated and subsequently edited by a human editor. For additional information, consult the Terms and Conditions.